Cory Berkland, PhD

Medical School Department Biomedical Engineering
Research Program Solid Tumor Therapeutics, Tumor Immunology
Cory Berkland

Researcher Background

Primary Academic Title

Professor, Biomedical Engineering, WashU Medicine

Training

  • 2014: Sabbatical, Sofinnova Ventures, Menlo Park, CA

Education

  • 1998: BS, Iowa State University, Ames, IA
  • 2001: MS, Univeristy of Illinois, Urbana, IL
  • 2003: PhD, University of Illinois, Urbana, IL

Research & Selected Publications

Research Interest

Cory Berkland’s lab studies pharmaceuticals and biomaterials with a particular emphasis on molecular design, drug formulation, and transport in the human body. Professor Berkland is a co-founder of Orbis Biosciences (acquired by Adare Pharmaceuticals), Savara Pharmaceuticals (NASDAQ:SVRA), Bond Biosciences, and several other start-ups. Professor Berkland is currently CSO of Bond Biosciences and is an executive and chairman of the board for Kinimmune and Axioforce.

Research Publications

Intralesional injection of CpG ODNs complexed with glatiramer acetate mitigates systemic cytokine toxicities and synergistically advances checkpoint blockade efficacy.
Authors:

Gong H, Griffin JD, Groer CE, one or more additional authors omitted Berkland CJ

Journal & Year:

Drug Deliv Transl Res • 2026

Lyophilized formulation development and characterization of stable glatiramer acetate/oligonucleotide polyplexes at clinically therapeutic strengths.
Authors:

Gong H, Luan X, Daniel Griffin J, one or more additional authors omitted Berkland CJ

Journal & Year:

Int J Pharm • 2026

Glatiramer Acetate Complexes CpG Oligodeoxynucleotides into Nanoparticles and Boosts Their TLR9-Driven Immunity.
Authors:

Gong H, Griffin JD, Groer CE, one or more additional authors omitted Berkland CJ

Journal & Year:

Mol Pharm • 2024